ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Ocera Therapeutics, Inc." (OCRX) Report Updated: Jul 28, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Ocera Therapeutics, Inc." (OCRX)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Pharmaceuticals
Competitors: SHPG, ANIP, LCI, AKRX

Stock Analysis

Rating: Monthly View

A
B
C
D
F
July August September October November December January February March April May June

Rating: Weekly View

This Week: D down no change
Last Week: D same downgrade
Two Weeks Ago: C up no change
service keys

"Ocera Therapeutics, Inc."© quotemedia

Company Profile

Ocera Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for liver and gastrointestinal diseases. Its product pipeline includes OCR-002 (ornithine phenylacetate), an injectable ammonia scavenger for the treatment and prevention of hyperammonemia and resultant acute hepatic encephalopathy in patients with liver cirrhosis and acute liver failure; and Zysa, a microspherical carbon adsorbent with selective adsorption profile for various unwanted substances/toxins involved in the pathology of liver and gastrointestinal diseases. Ocera Therapeutics, Inc. was incorporated in 2004 and is based in San Diego, California.

Recent News: "Ocera Therapeutics, Inc."